PharmaCyte Biotech Inc (PMCB)

[thenewmixer]

PMCB can not even apply for NASDAQ listings for at least 6 years from now:
The revenue standards are very clear and easily understandable:
“Companies must meet all of the criteria under at least one of the following standards. NASDAQ revenue standards are VERY clear. They must have either:

Standard No. 1: Earnings
The company must have aggregate pre-tax earnings in the prior three years of at least $11 million, in the previous two years at least $2.2 million, and no single year in the prior three years can have a net loss.

Or

Standard No. 2: Capitalization With Cash Flow
The company must have a minimum aggregate cash flow of at least $27.5 million for the past three fiscal years, with no negative cash flow in any of those three years. Also, its average market capitalization over the prior 12 months must be at least $550 million, and revenues in the previous fiscal year must be $110 million, minimum.”

Since PMCB is at best still 5 years if they were even allowed to proceed with Phase 2b which they won’t be, but even if they were. It would still be liberally 5 years before a CT 3 and subsequent requirements for sale of new drug could exist. Then at that point, PMCB would still need to increase revenue to standard for at least 3 years.

NASDAQ ARGUMENT OVER.